Search Results - "Van Dieren, J"

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis by Wervers, Kim, Vis, Marijn, Tchetveriko, Ilja, Gerards, Andreas H., Kok, Marc R., Appels, Cathelijne W. Y., Graaff, Wiebo L., Groenendael, Johannes H. L. M., Korswagen, Lindy‐Anne, Veris‐van Dieren, Josien J., Hazes, Johanna M. W., Luime, Jolanda J.

“…Objective Treat‐to‐target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional…”
Get full text

Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer by van der Kaaij, R. T., van Kessel, J. P., van Dieren, J. M., Snaebjornsson, P., Balagué, O., van Coevorden, F., van der Kolk, L. E., Sikorska, K., Cats, A., van Sandick, J. W.

“…Background Patients with hereditary diffuse gastric cancer and a CDH1 mutation have a 60–80 per cent lifetime risk of developing diffuse gastric cancer. Total…”
Get full text

Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis by Wervers, Kim, Luime, Jolanda J, Tchetverikov, Ilja, Gerards, Andreas H, Kok, Marc R, Appels, Cathelijne W Y, van der Graaff, Wiebo L, van Groenendael, Johannes H L M, Korswagen, Lindy-Anne, Veris-van Dieren, Josien J, Hazes, Johanna M W, Vis, Marijn

“…In a cohort of patients with newly diagnosed psoriatic arthritis (PsA) who received usual care, we investigated the impact of time elapsed to minimal disease…”
Get full text

Meta‐analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease by VAN DIEREN, J. M., HANSEN, B. E., KUIPERS, E. J., NIEUWENHUIS, E. E. S., VAN DER WOUDE, C. J.

“…Summary Background Thiopurines are widely used for the treatment of inflammatory bowel disease, but are associated with the development of side effects. It has…”
Get full text

Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic ARthritis study by Kasiem, FR, Luime, JJ, Vis, M, Kok, MR, Wervers, K, Gerards, AH, Appels, CWY, van der Graaff, WL, Starmans-Kool, MJF, Goekoop-Ruiterman, YPM, van Groenendael, JHLM, Korswagen, L-A, Veris-van Dieren, JJ, Hazes, JMW, Tchetverikov, I

“…Objective: This paper describes the baseline demographics, clinical characteristics, and patient-reported outcomes (PROs) according to clinical phenotype of…”
Get full text

Comparison between 1.5T and 3.0T MRI: both field strengths sensitively detect subclinical inflammation of hand and forefoot in patients with arthralgia by Krijbolder, DI, Verstappen, M, Wouters, F, Lard, LR, de Buck, PDM, Veris-van Dieren, JJ, Bloem, JL, Reijnierse, M, van der Helm-van Mil, AHM

“…Magnetic resonance imaging (MRI) of small joints sensitively detects inflammation. This inflammation, and tenosynovitis in particular, has been shown to…”
Get full text

Reducing Inappropriate Proton Pump Inhibitors Use for Stress Ulcer Prophylaxis in Hospitalized Patients: Systematic Review of De-Implementation Studies by Orelio, Claudia C., Heus, Pauline, Kroese-van Dieren, Judith J, Spijker, René, van Munster, Barbara C., Hooft, Lotty

“…Background A large proportion of proton pump inhibitor (PPI) prescriptions, including those for stress ulcer prophylaxis (SUP), are inappropriate. Our study…”
Get full text

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions by van der Leeuw, Matthijs S, Messelink, Marianne A, Tekstra, Janneke, Medina, Ojay, van Laar, Jaap M, Haitjema, Saskia, Lafeber, Floris, Veris-van Dieren, Josien J, van der Goes, Marlies C, den Broeder, Alfons A, Welsing, Paco M J

“…Biological disease-modifying antirheumatic drugs (bDMARDs) are effective in the treatment of rheumatoid arthritis. However, as bDMARDs may also lead to adverse…”
Get full text

Pharmacogenetics of thiopurine therapy in paediatric IBD patients by RIDDER, L., DIEREN, J. M., DEVENTER, H. J. H., STOKKERS, P. C. F., WOUDE, J. C. J., VUUREN, A. J., BENNINGA, M. A., ESCHER, J. C., HOMMES, D. W.

“…Summary Background  Azathioprine is widely used in the treatment of children with inflammatory bowel disease. The occurrence and type of adverse events to…”
Get full text

ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients by van Dieren, J M, van Vuuren, A J, Kusters, J G, Nieuwenhuis, E E S, Kuipers, E J, van der Woude, C J

“…The level of thiopurine methyltransferase (TPMT) activity is determined by a common genetic polymorphism. 1 It was shown that low TPMT activity is linked to a…”
Get full text

The clinical implications of staging laparoscopy in the diagnostic workup of gastric cancer patients: A population based study by van der Sluis, K., Vollebergh, M.A., Kodach, L.L., van Dieren, J.M., de Hingh, I.H.J.T., Wijnhoven, B.P.L., Verhoeven, R.H.A., Sandick, J.W. van

“…Since 2016, staging laparoscopy has been implemented in the diagnostic workup of patients with gastric cancer. Staging laparoscopy aims to detect incurable…”
Get full text

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer by Vollenbrock, S. E., Voncken, F. E. M., van Dieren, J. M., Lambregts, D. M. J., Maas, M., Meijer, G. J., Goense, L., Mook, S., Hartemink, K. J., Snaebjornsson, P., ter Beek, L. C., Verheij, M., Aleman, B. M. P., Beets‐Tan, R. G. H., Bartels‐Rutten, A.

“…Background Patients with a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer may benefit from non‐surgical…”
Get full text

External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts by Berbée, M., Muijs, C.T., Voncken, F.E.M., Wee, L., Sosef, M., van Etten, B., van Sandick, J.W., Warmerdam, F.A.R.M., de Haan, J.J., Oldehinkel, E., van Dieren, J.M., Boersma, L., Langendijk, J.A., van der Schaaf, A., Reitsma, J.B., Schuit, E.

“…•An existing prediction model for 2-year mortality in lung cancer patients, based on the predictive factors gross tumor volume and mean heart dose, was…”
Get full text

Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review by van der Sluis, L, van Dieren, J M, van der Post, R S, Bisseling, T M

“…More than 25 years ago, CDH1 pathogenic variants (PVs) were identified as the primary cause of hereditary diffuse gastric cancer (HDGC), an inherited cancer…”
Get full text

Correlation between symptoms, endoscopic features and treatment response in immunotherapy induced colitis by Geukes Foppen, M, Rozeman, E, Van Wilpe, S, Postma, C, Snaebjörnsson, P, Blank, C, Van Thienen, J, Van Leerdam, M, Van den Heuvel, M, Van Dieren, J, Haanen, J

Get full text

Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study by Borggreve, A S, Mook, S, Verheij, M, Mul, V E M, Bergman, J J, Bartels-Rutten, A, Ter Beek, L C, Beets-Tan, R G H, Bennink, R J, van Berge Henegouwen, M I, Brosens, L A A, Defize, I L, van Dieren, J M, Dijkstra, H, van Hillegersberg, R, Hulshof, M C, van Laarhoven, H W M, Lam, M G E H, van Lier, A L H M W, Muijs, C T, Nagengast, W B, Nederveen, A J, Noordzij, W, Plukker, J T M, van Rossum, P S N, Ruurda, J P, van Sandick, J W, Weusten, B L A M, Voncken, F E M, Yakar, D, Meijer, G J

“…Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR)…”
Get full text

PO-0708: Advanced age is no contraindication for chemoradiotherapy with curative intent in oesophageal cancer by Voncken, F, Van der Kaaij, R, Sikorska, K, Van Werkhoven, E, Van Dieren, J, Grootscholten, C, Snaebjornsson, P, Van Sandick, J, Aleman, B

Get full text

64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047 by Wagner, A.D, Kang, Y.K, Van Dieren, J, Mauer, M, Grabsch, H, Caballero, C, Kataoka, K, Atasoy, A, Cho, J.Y, Mohler, M, Roth, A, Salto-Tellez, M, Langer, R, Schuhmacher, C, Van Sandick, J, Van Grieken, N, Lordick, F

Get full text

Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis by Wervers, Kim, Luime, Jolanda J, Tchetverikov, Ilja, Gerards, Andreas H, Kok, Marc R, Appels, Cathelijne W Y, van der Graaff, Wiebo L, van Groenendael, Johannes H L M, Korswagen, Lindy-Anne, Veris-van Dieren, Josien J, Hazes, Johanna M W, Vis, Marijn

“…Psoriatic arthritis (PsA) is a multifaceted disease. Affecting joints, skin, entheses, and dactylitis, its effect on health-related quality of life (HRQOL)…”
Get full text

Comparison of disease activity measures in early psoriatic arthritis in usual care by Wervers, Kim, Luime, Jolanda J, Tchetverikov, Ilja, Gerards, Andreas H, Kok, Marc R, Appels, Cathelijne W Y, van der Graaff, Wiebo L, van Groenendael, Johannes H L M, Korswagen, Lindy-Anne, Veris-van Dieren, Josien J, Hazes, Johanna M W, Vis, Marijn

“…Abstract Objectives To compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis…”
Get full text